Dallas-based life science company ReCode Therapeutics has appointed Patricia “Trisha” Millican to its board of directors, bringing with her more than 20 years of experience in the life science industry.
ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer and a board member of ReCode Therapeutics, says Millcan brings “decades of proven strategic financial leadership and extensive biopharmaceutical industry experience to ReCode, an ideal complement to the existing makeup of our Board members.”
The CEO says the company looks forward to working closely with Millican as it prepares to “initiate the clinical development of our lead programs in primary ciliary dyskinesia and cystic fibrosis and execute our vision of powering the next wave of genetic medicines through superior delivery.”
Millican’s life sciences experience includes leading strategic finance and playing a key role in generating over $3 billion in capital via public, private, and debt financings, mergers and acquisitions, and corporate partnerships, the company said in a statement.
“ReCode is a true pioneer of genetic medicines and delivery, having developed technology that can deliver genetic medicines directly to specific organs and cells impacted by disease,” Millican said in a statement.
She looks to helping the team continue to advance “this important work so that more people may benefit from the potential of new precision genetic medicines.”
Millican is a strategic adviser to various life science companies and serves on the board of directors of Life Science Cares, San Diego. Most recently, she was chief financial officer of Metacrine Inc., where she led finance and investor relations from company formation through an initial public offering.
In November, ReCode announced that it formed a scientific advisory board and added Scientific Adviser Elliott Sigal, M.D., Ph.D.
Chaired by Daniel J. Siegwart, Ph.D., inaugural members of the board include Rafael Amado, M.D., Carrolee Barlow, M.D., Ph.D., Justin Hanes, Ph.D., and Eric Olson, Ph.D. These advisers will work closely with management to support ReCode’s expansion of its selective organ targeting (SORT) lipid nanoparticle (LNP) platform capabilities and advance its pipeline.
ReCode has offices in Dallas and Menlo Park, California.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
The advisers will work closely with management to support ReCode's expansion of its targeted-delivery genetics medicines platform and advance its pipeline of mRNA and gene correction therapeutics.
-
ReCode Therapeutics, a biopharmaceutical startup using a non-viral lipid nanoparticle delivery platform for gene therapies, has closed a $120 million extension to a funding round it raised last year to help bring its lead programs to human trials and “follow the science” to target new diseases. With a research team working out of BioLabs' life sciences facility at Pegasus Park, ReCode aims to grow its global team from about 70 to 100 over the next year.
-
In this week’s roundup of hires, promotions, and accolades in North Texas, you’ll also find news from Exela Technologies, Newmark, OrangeGrid, RailPros, Aimbridge Hospitality, Integrity Marketing Group, Smoothie King, Bank of Texas, MD7, Salvation Army, and more. Plus, you'll find board appointments including Texas Mutual Insurance, Zimperium, and the Ebby Halliday Foundation.
-
The TechFW board has named its 2022 leadership.
-
It's the first transition of chairs since the organization’s inception. The new chair was announced at the 2022 State of My Possibilities, a virtual event. Plus, Big Thought's Byron Sanders joined My Possibilities' Michael Thomas in a discussion of the importance of creativity and innovation in the charitable sector. Here's a takeaway.
